Yellow Fever: WHO Reports 200,000 Cases and 30,000 Deaths Annually Despite Effective Vaccine
Key Facts
- According to WHO, yellow fever causes an estimated 200,000 cases and 30,000 deaths annually, with 90% of cases occurring in Africa
- WHO data shows approximately 900 million people live in 34 African and 13 Latin American countries at risk of yellow fever transmission
- A single dose of yellow fever vaccine provides lifelong immunity in 99% of recipients, WHO reports, making the disease entirely preventable
- WHO identifies that case-fatality rates among severe yellow fever cases can reach 50%, with no specific antiviral treatment available
- According to WHO’s Eliminate Yellow Fever Epidemics (EYE) strategy launched in 2017, over 1 billion vaccine doses have been distributed, yet outbreaks continue in under-vaccinated populations
When Angola reported its first yellow fever case in December 2015, health officials initially treated it as a localized cluster. Within months, the country faced the worst yellow fever outbreak in decades—over 4,000 suspected cases, 400 deaths, and international spread to neighboring Democratic Republic of Congo and China. The outbreak exposed a brutal reality: despite having a safe, effective vaccine that provides lifelong immunity from a single dose, yellow fever persists as a major killer in Africa and Latin America. The problem isn’t scientific—it’s logistical, financial, and political. Vaccine supply hasn’t kept pace with population growth in endemic regions. Routine immunization coverage has stagnated or declined in some countries. And outbreak response mechanisms, while improving, still struggle to contain transmission once it starts. This article examines what WHO’s data reveals about yellow fever’s persistent burden, why a vaccine-preventable disease still kills 30,000 people annually, and whether global health initiatives can finally eliminate a threat that’s been recognized since Carlos Juan Finlay’s pioneering yellow fever research in the 19th century.
What Is Yellow Fever? — WHO’s Definition
According to WHO, yellow fever is an acute viral hemorrhagic disease transmitted by infected mosquitoes, caused by the yellow fever virus—a flavivirus closely related to dengue, Zika, and West Nile viruses. The disease is named for the jaundice (yellowing of skin and eyes) that affects some patients due to liver damage. WHO’s framework classifies yellow fever as a vaccine-preventable disease of major public health importance, endemic in tropical regions of Africa and Central and South America where the Aedes and Haemagogus mosquito vectors are present.
WHO distinguishes three transmission cycles. Sylvatic (jungle) yellow fever occurs in tropical rainforests where monkeys are the primary reservoir and forest-dwelling mosquitoes transmit virus between monkeys and occasionally to humans who enter forests. Intermediate yellow fever occurs in humid or semi-humid savannas where mosquitoes infect both monkeys and humans in small-scale epidemics—this is the most common outbreak pattern in Africa. Urban yellow fever involves transmission between humans by Aedes aegypti mosquitoes in densely populated areas, creating epidemic potential for rapid spread affecting thousands.
The critical public health distinction WHO makes is that yellow fever, unlike dengue or malaria, has an extraordinarily effective vaccine. A single dose provides lifelong immunity in 99% of recipients. The vaccine has been used since the 1930s—developed by Max Theiler, whose work earned a Nobel Prize—and has an excellent safety profile. This means yellow fever is entirely preventable. That it continues to kill tens of thousands annually reflects not biological inevitability but failures of vaccine delivery, health system capacity, and political commitment.
Global Burden
WHO estimates that yellow fever causes approximately 200,000 cases and 30,000 deaths annually worldwide, though the true burden is likely higher due to underreporting—many cases in remote areas never reach health facilities or are misdiagnosed as other febrile illnesses. The disease burden is heavily concentrated in Africa, which accounts for 90% of reported cases globally. According to WHO’s yellow fever disease burden data (https://www.who.int/news-room/fact-sheets/detail/yellow-fever), 34 countries in Africa are considered at risk for yellow fever transmission, with an estimated 508 million people living in these areas.
Latin America faces ongoing risk despite lower reported incidence. Thirteen countries in Central and South America are endemic or have regions at risk, with approximately 400 million people potentially exposed. Brazil has experienced recurring outbreaks, including a major 2016-2018 outbreak that spread from forest areas to populated coastal regions, causing over 2,000 cases and 750 deaths. The proximity to major urban centers with large susceptible populations creates epidemic potential reminiscent of historical urban yellow fever that devastated cities before vaccination.
The geographic distribution reflects vector ecology and vaccination coverage. Aedes aegypti—the primary urban vector—is widely distributed across tropical and subtropical regions globally. Its presence in densely populated cities creates the potential for explosive urban outbreaks when the virus is introduced to under-vaccinated populations. According to CDC yellow fever data (https://www.cdc.gov/yellowfever/index.html), recent decades have seen Aedes aegypti expansion driven by urbanization, climate change, and declining vector control programs, increasing the population at risk.
Age distribution varies by setting. In endemic areas with ongoing transmission, children bear disproportionate burden if routine immunization coverage is low—they’re born into risk without vaccine protection. In outbreak settings, all age groups are affected based on vaccination history. WHO surveillance data shows that adults who’ve never been vaccinated and enter endemic areas (travelers, migrants, displaced populations) face high risk.
Case-fatality rates are alarming. WHO reports that among patients who develop severe yellow fever—approximately 15% of symptomatic cases—case-fatality can reach 50% even with supportive care, because there’s no specific antiviral treatment. This creates a tragic pattern: most people infected with yellow fever virus experience mild or no symptoms, but those who develop severe disease face a coin-flip chance of death. And this occurs despite having a vaccine that could have prevented infection entirely.
The burden measurement challenges are substantial. Yellow fever diagnosis requires laboratory confirmation (serology, PCR, viral isolation), but testing capacity is limited in many endemic countries. Clinical diagnosis is unreliable—yellow fever symptoms overlap with malaria, dengue, leptospirosis, viral hepatitis, and other endemic diseases. WHO estimates that only 12-33% of actual cases are detected and reported. The 200,000 annual cases figure is a modeled estimate based on limited surveillance data—the true burden could be higher.
Outbreak patterns have intensified. According to research published in PLOS Neglected Tropical Diseases (https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0008304), yellow fever outbreaks increased in frequency and geographic spread from 2000-2020, driven by declining vaccination coverage, population growth in at-risk areas, urbanization, climate change affecting mosquito distribution, and insufficient outbreak response capacity. The 2016-2018 Brazil outbreak and 2015-2016 Angola/DRC outbreak demonstrated that despite vaccine availability, large susceptible populations remain vulnerable.
Causes, Transmission and Risk Factors
Yellow fever is caused by yellow fever virus, a single-stranded RNA virus in the genus Flavivirus, family Flaviviridae. The virus is transmitted exclusively by mosquito bite—humans cannot transmit yellow fever directly to other humans. WHO identifies two primary vector genera: Aedes mosquitoes (particularly A. aegypti) for urban and some intermediate transmission, and Haemagogus and Sabethes mosquitoes for sylvatic transmission in South America. In Africa, several Aedes species including A. africanus, A. bromeliae, and A. furcifer transmit yellow fever in different ecological zones.
The transmission cycle begins when a mosquito bites an infected human or monkey during the viremic period (when virus circulates in blood, typically 3-6 days after infection onset). The virus replicates in the mosquito over 9-12 days (extrinsic incubation period), after which the mosquito remains infectious for life and can transmit virus to any subsequent person it bites. Human incubation period averages 3-6 days from infectious bite to symptom onset.
WHO’s risk factor framework identifies individual, vector, and environmental determinants. Individual risk factors include lack of yellow fever vaccination (the dominant risk), occupation or activities requiring entry into forest areas where sylvatic transmission occurs, living in or traveling to endemic areas during outbreaks, and age (no age-specific immunity, but older adults and infants face higher severe disease risk). There’s no evidence of genetic susceptibility differences by ethnicity—risk is entirely environmental and vaccination-based.
Vector factors include Aedes aegypti distribution and density, which WHO data shows has expanded dramatically over recent decades. This mosquito thrives in urban environments, breeding in artificial water containers (tires, drums, flower pots, discarded containers) created by human activity. Poor water storage practices in areas with inadequate piped water supply create abundant breeding sites. Climate conditions—temperature, rainfall, humidity—affect mosquito breeding and virus replication rates. Research in The Lancet Planetary Health (https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(20)30097-7/fulltext) shows climate change is expanding Aedes mosquito habitat into previously unsuitable areas, including higher altitudes and latitudes.
Environmental and social determinants are critical. Deforestation and land-use change increase human-wildlife contact at forest edges, facilitating spillover from sylvatic cycles. Urbanization creates dense susceptible populations if vaccination coverage is inadequate. Population displacement from conflict or economic migration moves people between endemic and non-endemic areas. Poverty limits access to housing that excludes mosquitoes, water storage that doesn’t create breeding sites, and healthcare when illness occurs.
The vaccination gap is the fundamental risk factor. WHO data shows that routine immunization coverage in some endemic countries is below 60%—far short of the 80-90% coverage needed to prevent epidemics. Vaccine supply shortages have created periodic stockouts. And vaccination catch-up campaigns, while effective when implemented, don’t reach all areas due to access barriers, insecurity, or resource limitations. The result: large cohorts of unvaccinated children and adults remain susceptible.
Signs, Symptoms and Health Impacts
WHO identifies two clinical phases of yellow fever in the 15% of infections that progress beyond asymptomatic or mild disease. The acute phase begins 3-6 days after infection with sudden onset of fever, chills, severe headache, back pain, generalized muscle pain, nausea, vomiting, and fatigue. Many patients improve after 3-4 days and recover fully—this represents 85% of symptomatic cases.
But approximately 15% of symptomatic patients enter a toxic phase within 24 hours of apparent improvement. WHO reports this second phase is characterized by return of high fever, jaundice (yellowing of skin and eyes from liver damage), abdominal pain with vomiting, bleeding from mouth/nose/eyes/stomach (hemorrhagic manifestations), decreased urination (kidney failure), and altered mental status. Blood tests show elevated liver enzymes, prolonged clotting times, and declining platelet counts. Multi-organ failure can develop rapidly: liver necrosis, kidney failure, cardiovascular collapse, and encephalopathy.
Case-fatality in this toxic phase reaches 50% according to WHO surveillance data, even with optimal supportive care. Death typically occurs within 7-10 days of symptom onset. Patients who survive toxic phase yellow fever generally recover completely, though convalescence can take weeks to months. There’s no evidence of chronic yellow fever infection or long-term sequelae in survivors beyond the recovery period—unlike some viral hemorrhagic fevers where prolonged complications occur.
Diagnostic challenges complicate clinical management. Yellow fever symptoms in the acute phase are nonspecific and overlap with numerous other tropical infections. According to WHO clinical guidelines, yellow fever should be suspected in anyone presenting with acute fever and jaundice in endemic areas or within 10 days of travel to endemic areas, especially if unvaccinated. But definitive diagnosis requires laboratory confirmation: detection of yellow fever virus RNA by PCR, detection of virus-specific IgM antibodies, or viral isolation (rarely performed).
Laboratory capacity in endemic countries is often limited. Many health facilities lack the equipment, reagents, and trained personnel for yellow fever diagnostics. Samples must often be transported to reference laboratories, causing delays. Cross-reactivity between flavivirus antibody tests (yellow fever, dengue, Zika, West Nile) creates false positives requiring confirmatory testing. The result: many cases are never confirmed, outbreak detection is delayed, and case management proceeds on clinical suspicion.
The broader health impacts extend beyond individual cases. Outbreaks strain healthcare systems—hospitals become overwhelmed with severe cases requiring intensive supportive care, blood products, and dialysis in settings where these resources are scarce. Healthcare workers face occupational exposure risk if infection control is inadequate. Economic impacts from outbreak response costs, lost productivity, and reduced tourism can be substantial. And the pattern parallels other viral hemorrhagic fevers: just as Lassa fever creates acute health system challenges during outbreaks, yellow fever response diverts resources from routine health services.
Treatment and Health Response
WHO reports there is no specific antiviral treatment for yellow fever—management is entirely supportive care aimed at maintaining organ function while the immune system clears the virus. Supportive care includes fever and pain management (avoiding aspirin and NSAIDs which increase bleeding risk), maintenance of fluid and electrolyte balance, blood pressure support, blood transfusions for hemorrhage, dialysis for kidney failure, and intensive monitoring. In high-resource settings with access to intensive care, case-fatality can be reduced, but most endemic areas lack this capacity.
Access to quality supportive care is the major treatment barrier. Many endemic regions have limited hospital capacity, few or no intensive care beds, inadequate blood banking, and no dialysis availability. Healthcare workers may lack training in managing viral hemorrhagic fever. Infection control supplies—gloves, gowns, face protection—may be insufficient, creating nosocomial transmission risk. The result: case-fatality rates in resource-limited settings during outbreaks can exceed 50% even though better outcomes are achievable with optimal care.
WHO’s clinical management guidelines (https://www.who.int/publications/i/item/clinical-management-of-yellow-fever) emphasize early supportive care and isolation to prevent mosquito access to patients during viremic period (reducing onward transmission). But guideline dissemination and implementation are inconsistent. Many health workers in endemic areas have never seen a yellow fever case and may not recognize the disease early. Diagnostic delays mean patients may progress to toxic phase before yellow fever is even suspected.
Outbreak response capacity has improved but remains inadequate. WHO’s Epidemic and Pandemic Preparedness Team coordinates international response to yellow fever outbreaks, including rapid risk assessment, deployment of emergency vaccination campaigns, vector control support, and laboratory surge capacity. According to WHO’s yellow fever outbreak response framework (https://www.who.int/publications/i/item/yellow-fever-outbreak-readiness-and-response), response is triggered when laboratory-confirmed cases are detected, aiming to vaccinate susceptible populations within outbreak zones before transmission amplifies.
But response timelines are often too slow. From initial cases to laboratory confirmation can take weeks. Emergency vaccination campaigns require vaccine procurement (from the global stockpile), campaign planning, community mobilization, and logistics—often taking additional weeks to months. By the time mass vaccination begins, substantial transmission may have already occurred. The 2015-2016 Angola outbreak illustrated this: over 400 deaths occurred before emergency vaccination covered the at-risk population.
The global vaccine stockpile, managed by the International Coordinating Group (ICG) on Vaccine Provision, maintains approximately 6 million doses for outbreak response. But large outbreaks can quickly deplete this reserve, creating difficult allocation decisions when multiple countries request vaccines simultaneously. During the 2016 Angola/DRC outbreak, stockpile depletion forced use of fractional dosing (one-fifth of a standard dose) to extend supply—a scientifically supported strategy that provides shorter-term protection but reflects the constraint that global vaccine production capacity hasn’t kept pace with need.
Prevention and WHO Strategies
WHO frames yellow fever prevention through two complementary strategies: routine immunization to build population immunity in endemic areas, and emergency vaccination campaigns to control outbreaks. The vaccine—a live-attenuated virus strain called 17D—is one of the safest and most effective vaccines ever developed. A single dose provides protective immunity within 30 days in 99% of recipients and provides lifelong protection according to current WHO guidance (previously a booster was recommended after 10 years, but evidence showed this wasn’t necessary).
Routine immunization is the cornerstone of prevention. WHO recommends yellow fever vaccine be integrated into national childhood immunization programs in all countries with risk of yellow fever transmission. The vaccine is typically given at 9-12 months of age alongside measles vaccine. Target coverage is at least 80-90% to establish herd immunity that prevents epidemics. According to WHO’s immunization coverage data (https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/yellow-fever), coverage in endemic countries varies widely—from over 90% in some nations to below 60% in others.
The coverage gap is deadly. Millions of children in endemic areas remain unvaccinated due to health system weaknesses, vaccine stockouts, access barriers in remote regions, conflict and insecurity preventing vaccination teams, and competing priorities for limited health budgets. The result: susceptible populations accumulate, creating the conditions for outbreaks. Just as vaccines save an estimated 4.5 million lives yearly, yet 20 million children miss basic shots, yellow fever vaccination gaps persist despite the vaccine’s proven efficacy.
Preventive vaccination campaigns target specific at-risk populations: mass campaigns in outbreak-prone regions to rapidly build population immunity, vaccination of travelers to endemic areas (many countries require proof of yellow fever vaccination for entry), and catch-up campaigns for age cohorts missed by routine immunization. WHO’s Eliminate Yellow Fever Epidemics (EYE) strategy, launched in 2017, prioritizes preventive mass vaccination in 40 at-risk countries in Africa and the Americas, aiming to protect over 1 billion people by 2026.
Vector control complements vaccination. WHO recommends integrated vector management targeting Aedes aegypti: elimination of mosquito breeding sites through improved water storage and waste management, larviciding of water containers, indoor residual spraying in outbreak settings, use of insecticide-treated materials, and community mobilization for environmental management. But vector control is resource-intensive and sustainability is challenging—many countries have weakened or eliminated vector control programs over recent decades, contributing to mosquito resurgence.
Surveillance is critical for early outbreak detection. WHO’s Integrated Disease Surveillance and Response (IDSR) framework includes yellow fever as a priority notifiable disease requiring immediate investigation of suspected cases. Rapid diagnostic confirmation enables timely outbreak response. But surveillance capacity in many endemic countries is limited—laboratory networks are incomplete, case reporting is delayed, and linkage between surveillance and response is weak.
Environmental and social interventions address upstream determinants. Improved housing that excludes mosquitoes, piped water supply that eliminates water storage containers, waste management that reduces mosquito breeding sites, and land-use planning that minimizes human-forest interface contact all reduce transmission risk. But these require multi-sectoral development investment beyond the health sector.
WHO’s Global Efforts and the EYE Strategy
WHO’s yellow fever work has evolved from reactive outbreak response to proactive prevention. The turning point was the 2016 Angola/DRC outbreak and concurrent Brazil outbreak, which demonstrated that despite vaccine availability, large susceptible populations remained at risk and outbreak response mechanisms were inadequate to prevent mass casualties.
In response, WHO launched the Eliminate Yellow Fever Epidemics (EYE) strategy in 2017 in partnership with UNICEF and Gavi, the Vaccine Alliance. According to WHO’s EYE documentation (https://www.who.int/initiatives/eye-strategy), the strategy aims to protect at-risk populations in 40 countries (27 in Africa, 13 in the Americas) through three pillars: protect at-risk populations through vaccination, prevent international spread through surveillance and rapid response, and contain outbreaks rapidly through emergency response systems.
Progress has been substantial but incomplete. From 2017-2023, the EYE partnership delivered over 1 billion yellow fever vaccine doses through preventive campaigns and outbreak response. Routine immunization coverage increased in several endemic countries. Outbreak detection and response timelines improved with enhanced surveillance and pre-positioned vaccine stockpiles in regional hubs. Laboratory networks expanded diagnostic capacity. Several countries achieved national vaccination coverage targets.
But challenges persist. The COVID-19 pandemic disrupted yellow fever vaccination campaigns in 2020-2021, creating immunity gaps. Vaccine supply remains constrained—global production capacity is approximately 80-100 million doses annually, insufficient to meet both routine immunization needs and outbreak response demand simultaneously when large outbreaks occur. Only four manufacturers produce WHO-prequalified yellow fever vaccine, creating vulnerability to production disruptions. And political instability, conflict, and health system weaknesses in some endemic countries prevent reaching all at-risk populations.
Financing is chronically inadequate. Gavi has committed substantial funding for yellow fever vaccination in eligible countries, but domestic financing for routine immunization remains insufficient in many endemic nations. The EYE strategy estimated that achieving elimination goals requires approximately $1 billion over 10 years—WHO reports funding has fallen short of this target, with implementation proceeding more slowly than planned in some countries.
The World Health Assembly has not adopted a specific resolution on yellow fever eradication, reflecting recognition that current tools and resources are insufficient for eradication—the existence of sylvatic cycles in primates means virus cannot be eliminated from nature. But elimination of yellow fever epidemics (preventing large outbreaks through high population immunity) is achievable with sustained vaccination programs.
Regional initiatives vary in progress. In Africa, the Integrated Yellow Fever Surveillance and Immunization in Africa initiative has strengthened surveillance and built immunization capacity, but coverage gaps persist in several countries. In the Americas, the Pan American Health Organization (PAHO) has coordinated vaccination efforts, but Brazil’s recurring outbreaks demonstrate ongoing vulnerability in areas where vaccination coverage declined or never reached high levels.
The editorial question is whether the world will finally prioritize yellow fever prevention or continue the cycle of panic-and-neglect: outbreaks trigger emergency response and temporary funding increases, then attention and resources drift away until the next outbreak. We’ve had an effective vaccine for 90 years. The technology isn’t the barrier. From world history to contemporary global health, yellow fever has taught us that scientific solutions mean nothing without sustained delivery systems, adequate financing, and political commitment.
The EYE strategy offers a framework, but implementation depends on sustained funding, vaccine manufacturing scale-up, health system strengthening in endemic countries, and international coordination. Will donor commitments continue beyond initial enthusiasm? Will endemic countries prioritize immunization amid competing demands? Will vaccine manufacturers invest in expanded production capacity? The 2030 target for eliminating yellow fever epidemics is achievable—but only if the lessons from decades of outbreaks finally translate into sustained prevention rather than reactive crisis management. Similar to other vaccine-preventable diseases where delivery gaps persist despite having effective tools, as exemplified by concerns about fake medicines killing an estimated 250,000 children through compromised supply chains, yellow fever elimination requires not just vaccines but trustworthy, functioning health systems that can deliver them. And as sustained campaigns like World Cancer Day awareness efforts demonstrate, achieving health outcomes requires long-term commitment beyond crisis moments—a lesson yellow fever keeps teaching us but we seem reluctant to learn.
FAQ
What is yellow fever and how is it transmitted?
WHO defines yellow fever as an acute viral hemorrhagic disease caused by yellow fever virus (a flavivirus) transmitted by infected mosquitoes, primarily Aedes aegypti in urban settings and Haemagogus mosquitoes in forest areas. Mosquitoes acquire the virus from infected humans or monkeys, then transmit to susceptible individuals through bites. There is no direct human-to-human transmission. The disease is endemic in tropical Africa and Central/South America.
How effective is the yellow fever vaccine and how long does protection last?
WHO reports that a single dose of yellow fever vaccine (17D live-attenuated strain) provides protective immunity in 99% of recipients within 30 days and confers lifelong protection. Previously WHO recommended boosters after 10 years, but evidence showed one dose is sufficient for life in most recipients. The vaccine has been used since the 1930s with an excellent safety profile, making yellow fever entirely vaccine-preventable.
What are the symptoms and how deadly is yellow fever?
WHO identifies that 85% of infections are asymptomatic or cause mild fever, headache, muscle pain, and nausea that resolve within days. However, 15% of symptomatic cases progress to severe disease with jaundice (yellowing from liver damage), hemorrhage, kidney failure, and multi-organ failure. Among severe cases, case-fatality rates reach 50% even with supportive care because no specific antiviral treatment exists. Death typically occurs within 7-10 days of symptom onset.
How many people are affected by yellow fever annually?
WHO estimates yellow fever causes approximately 200,000 cases and 30,000 deaths annually worldwide, though true burden is likely higher due to underreporting. Africa accounts for 90% of cases. An estimated 900 million people live in at-risk areas across 34 African and 13 Latin American countries. Large outbreaks can affect thousands—Angola’s 2015-2016 outbreak caused over 4,000 suspected cases and 400 deaths.
Why does yellow fever persist despite having an effective vaccine?
WHO identifies several barriers: inadequate routine immunization coverage (below 80-90% needed for herd immunity) in many endemic countries due to health system weaknesses and access barriers; limited global vaccine production capacity (80-100 million doses annually) insufficient for simultaneous routine immunization and large outbreak response; vaccine stockouts; population growth in endemic areas outpacing vaccination programs; and insufficient sustained financing for prevention. The EYE strategy aims to address these gaps but requires sustained political and financial commitment.
Sources
- World Health Organization. (2024). Yellow fever. Retrieved from https://www.who.int/health-topics/yellow-fever
- World Health Organization. (2023). Yellow fever fact sheet. Retrieved from https://www.who.int/news-room/fact-sheets/detail/yellow-fever
- Garske, T., et al. (2014). Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLOS Medicine, 11(5), e1001638.
- World Health Organization. (2018). Eliminate Yellow Fever Epidemics (EYE): a global strategy, 2017-2026. Retrieved from https://www.who.int/publications/i/item/9789241513661
DISCLAIMER
This article adapts publicly available information from WHO’s Yellow Fever page. This content is for informational and educational purposes only and does not constitute medical advice. ObserverVoice.com is a news and information platform—not a healthcare provider.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
